ReviewRenal failure2026
Bibliometric analysis of sacubitril/valsartan in the management of chronic kidney disease (2013-2025).
Review in Renal failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) is a global health issue with progressive renal decline. Sacubitril-valsartan, the first angiotensin receptor-neprilysin inhibitor (ARNI), offers a novel therapeutic approach with potential renoprotective effects in patients with CKD.
methodsA bibliometric analysis was conducted using 254 peer-reviewed articles retrieved from the Web of Science Core Collection (January 2013 to June 2025). Search terms included 'sacubitril/valsartan' and keywords related to CKD. Data were analyzed and visualized using CiteSpace V6.3.R6, VOSviewer 1.6.20, and R software (Bibliometrix package). Techniques included coauthorship, co-citation, co-occurrence analysis, burst detection, and thematic mapping.
resultsThe literature on sacubitril/valsartan in CKD has increased steadily over time, with China and the United States contributing the largest number of publications; the United States showed higher betweenness centrality (0.33). Novartis and Harvard University were among the most productive sources, while
conclusionsThis bibliometric analysis delineates the evolving research landscape of sacubitril/valsartan in CKD from 2013 to 2025, highlighting sustained growth, key contributors, and emerging research themes. The findings underscore increasing attention to cardiorenal applications, precision medicine, and combination therapies, while also identifying persistent gaps related to long-term safety, dialysis dosing, and renoprotective mechanisms. These insights provide a structured reference to inform future clinical and translational research in CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.